Neuroprotective effects of ursodeoxycholic acid in comparison to Diazepam against Pilocarpine-induced status epilepticus in experimental rats
DOI:
https://doi.org/10.48047/V9.I1.2023.382-393Keywords:
Status epilepticus(SE), Pilocarpine(Pilo), Diazepam(DZM), Lithium Carbonate(LiCa), Ursodeoxycholic-acid(UDCA), Reduced Glutathione Levels (GSH), Tumor Necrosis Factor-αlpha(TNF-α), Small dose(S.D), Large dose(L.D)Abstract
Background: Epilepsy is the fourth most frequent neurological disorder worldwide. Epilepsy can be diagnosed if someone has two or more spontaneous seizures. Subtypes M1 and M3 of the receptor are affected by pilocarpine, with the M3 receptor having the ability to activate phospholipase C. In this way, the second messenger's inositol triphosphate, diacylglycerol, calcium, and protein kinase are produced. Because of this, M3 cholinergic agonists cause calcium to be upregulated, leading to smooth muscle contraction. Ursodeoxycholic acid is an effective drug for treating cholestatic liver disease. There are a number of interconnected and synergistic ways in which ursodeoxycholic acid affects the liver.
Method: Thirty adult male Wistar rats, weighing 200 ± 20 g, were utilized in this study. Group I (negative control): Rats will be received of N/S (0.5 ml/kg)
Group II (Sco+LiCa+Pilo): Rats received LiCa, 127 mg/kg, followed by pilocarpine administration (30 mg/kg).
Scopolamine (1 mg/kg in rats) is also given to the rats 30 min before pilocarpine administration.
Group III(Diazepam ):Epileptic rats treated with diazepam (20 mg/kg) were started 2 h after the beginning of SE. Group IV (min. dose of UDCA): Epileptic rats will receive UDCA 25 mg/kg/day. Group V (max. dose of UDCA): Epileptic rats will receive UDCA 100 mg/kg/day .
Result: Based on measurement of markers: TNF-α and GSH, we reported increase the level of TNF-α and decrease the level of GSH when given pilocarpine, while we found rise in the GSH level and decrease in the level of TNF-α in UDCA-treated group
Conclusion: It can be concluded that the UDCA improves the biochemical alterations (decreases GSH & increases TNF) that occur after S.E., and UDCA has the same effect when compared with the diazepam effect.
Downloads
References
Goldenberg, M.M. Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. Pharm. Ther. 2010, 35, 392–415.
Stafstrom, C.E.; Carmant, L. Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb. Perspect. Med. 2015, a022426.
Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: Report of the ILAE Task Force on Classification of Status
Epilepticus. Epilepsia. 2015;56:1515–23.
Joshi S, Kapur J. GABAA receptor plasticity during status epilepticus. In: Noebels
JL, et al., editors. Jasper's Basic Mechanisms of the Epilepsies. Bethesda, MD:
Oxford University Press; 2012. pp. 545–51.
Delli K, Spijkervet FK, Kroese FG, Bootsma H, Vissink A. Xerostomia. Monogr Oral
Sci. 2014;24:109-25.
Davies AN, Thompson J. Parasympathomimetic drugs for the treatment of salivary
gland dysfunction due to radiotherapy. Cochrane Database Syst Rev. 2015 Oct
;2015(10):CD003782.
Carlson AB, Kraus GP. StatPearls [Internet]. StatPearls Publishing; Treasure Island
(FL): Aug 22, 2022. Physiology, Cholinergic Receptors.
Pronin AN, Wang Q, Slepak VZ. Teaching an Old Drug New Tricks: Agonism, Antagonism, and Biased Signaling of Pilocarpine through M3 Muscarinic Acetylcholine Receptor. Mol. Pharmacol. 2017 Nov;92(5):601-612.
Hayes JF, Pitman A, Marston L, Walters K, Geddes JR, King M, Osborn DP. Selfharm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study. JAMA Psychiatry. 2016 Jun 01;73(6):630-7.
Perveen T, Haider S, Mumtaz W, Razi F, Tabassum S, Haleem DJ. Attenuation of
stress-induced behavioral deficits by lithium administration via serotonin
metabolism. Pharmacol Rep. 2013;65(2):336-42.
Sheng R, Zhang LS, Han R, Gao B, Liu XQ, Qin ZH. Combined prostaglandin E1 and
lithium exert potent neuroprotection in a rat model of cerebral
ischemia. ActaPharmacol Sin. 2011 Mar;32(3):303-10.
Pergolizzi JV, Philip BK, Leslie JB, Taylor R, Raffa RB. Perspectives on transdermal
scopolamine for the treatment of postoperative nausea and vomiting. J
ClinAnesth. 2012 Jun;24(4):334-45.
Zhang XC, Farrell N, Haronian T, Hack J. Postoperative Anticholinergic Poisoning:
Concealed Complications of a Commonly Used Medication. J Emerg Med. 2017
Oct;53(4):520-523.
Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine
receptor in psychiatric disorder. Br J Psychiatry. 2001 Nov;179:390-6.
Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid
therapy in gallbladder disease, a story not yet completed. World J
Gastroenterol. 2013 Aug 21;19(31):5029-34.
Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ.
Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic
applications. ClinSci (Lond). 2011 Dec;121(12):523-44.
Rodrigues CM, Spellman SR, Sola S, Grande AW, Linehan-Stieers C, Low WC, et al.
Neuroprotection by a bileacid in an acute stroke model in the rat. J Cereb Blood
Flow Metab. 2002;22(4):463-71.
Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic
acid in inhibiting apoptosis bymodulating mitochondrial membrane perturbation. J
Clin Invest. 1998;101(12):2790-9.
Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, et al.
Tauroursodeoxycholic acid partiallyprevents apoptosis induced by 3-nitropropionic
acid: evidence for a mitochondrial pathway independent of thepermeability
transition. J Neurochem. 2000 Dec;75(6):2368-79.
Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe IN, et al. Ursodeoxycholic
acid diminishes Fas-ligandinducedapoptosis in mouse hepatocytes. Hepatol.
;36(1):49-54.
Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, et al.Tauroursodeoxycholicacid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Molecul Neurobiol.2012;46(2):475-86.
Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC.
Tauroursodeoxycholic acid, a bile acid, isneuroprotective in a transgenic animal
model of Huntington's disease. Proc Nat AcadSci U S A.2002;99(16):10671-6.
Morrison Jr JM, Pritchard HD, Braude MC, D'Aguanno W. Plasma and brain lithium
levels after lithium carbonate and lithium chloride administration by different routes
in rats. Proceedings of the Society for Experimental Biology and Medicine. 1971
Jul;137(3):889-92.
Hirsch E, Baram TZ, Snead III OC. Ontogenic study of lithium-pilocarpine-induced
status epilepticus in rats. Brain research. 1992 Jun 26;583(1-2):120-6.
Racine RJ. Modification of seizure activity by electrical stimulation, II: motor seizure.
ElectroencephalogrClinNeurophysiol 1972;32:281–94
Pitkänen A, Kharatishvili I, Narkilahti S, Lukasiuk K, Nissinen J. Administration of
diazepam during status epilepticus reduces development and severity of epilepsy in
rat. Epilepsy research. 2005 Jan 1;63(1):27-42.
Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J.
Ursodeoxycholic acid treatment in a rat model of cancer cachexia. Journal of
cachexia, sarcopenia and muscle. 2012 Mar;3(1):31-6.
Bradley J.R. TNF-Mediated inflammatory disease. J. Pathol. 2008;214:149–160.
doi: 10.1002/path.2287. [PubMed] [CrossRef] [Google Scholar]
Horiuchi T., Mitoma H., Harashima S., Tsukamoto H., Shimoda T. Transmembrane
TNF-alpha: Structure, function and interaction with anti-TNF
agents. Rheumatology. 2010;49:1215–1228.
doi: 10.1093/rheumatology/keq031. [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Han K, Wang QY, Wang CX, et al. (2018). Ghrelin improves pilocarpine-induced
cerebral cortex inflammation in epileptic rats by inhibiting NF-κB and TNF-α. Mol
Med Rep, 18(4): 3563–3568.
Atreya R, Neurath MF. IBD pathogenesis in 2014: Molecular pathways controlling
barrier function in IBD. Nat Rev GastroenterolHepatol12: 67–68, 2015.
P. Casellas, S. Galiegue, and A. S. Basile, “Peripheral benzodiazepine receptors and mitochondrial function,” Neurochemistry International, vol. 40, no. 6, pp. 475-486, 2002.
M. Schlumpf, R. Parmar, E. E. Bütikofer et al., “Delayed developmental neuro- and immunotoxicity of benzodiazepines,” Archives of Toxicology, Supplement, vol. 17,pp. 261–287, 1995.
R. Lazzarini, P. C. Maiorka, J. Liu, V. Papadopoulos, and J. Palermo-Neto,
“Diazepam effects on carrageenan-induced inflammatory paw edema in rats: Role of
nitric oxide,” Life Sciences, vol. 78, no. 26, pp. 3027–3034, 2006.
S. R. Torres, T. S. Fröde, G. M. Nardi et al., “Anti-inflammatory effects of peripheral
benzodiazepine receptor ligands in two mouse models of inflammation,” European
Journal of Pharmacology, vol. 408, no. 2, pp. 199–211, 2000.
Halprin, Kenneth (1967). "The Measurement of Glutathione in Human Epidermis
using glutathione reductase." Journal of Investigative Dermatology 1967; 48 (2):
Scholz RW, Graham KS, Gumpricht EReddy CC. Mechanism of interaction of
vitamin E and glutathione in the protection against membrane lipid peroxidation. Ann
NY AcadSci 1989; 1989:570:514-7. Hughes RE. Reduction of dehydroascorbic acid by
animal tissues. Nature 1964; 203: 1068-9.
Brozek G, Hort J, Koma´rek V, Langmeier M & Mares P (2000) Interstrain
differences in cognitive functions in rats in relation to status epilepticus. Behav Brain
Res 112, 77–83.
Treiman DM (1955) Electroclinical features of status epilepticus. J ClinNeurophysiol
, 343–362.
Freitas RM, Souza FCF, Vasconcelos SMM, Viana GSB & Fonteles MMF (2003)
Acute alterations of neurotransmitters levels in striatum of young rat after
pilocarpine-induced status epilepticus. ArqNeuropsiquiatr 61, 430–433.
Simonie´ A, Laginja J, Varljen J, Zupan G & Erakovie´ V (2000) Lithium plus
Pilocarpine-Induced Status Epilepticus: Biochemical Changes. Neurosci Res 36, 157–
Arisawa S, Ishida K, Kameyama N, Ueyama J, Hattori A, Tatsumi Y, Hayashi H, Yano M, Hayashi K, Katano Y, Goto H. Ursodeoxycholic acid induces glutathione synthesis through activation of the PI3K/Akt pathway in HepG2 cells. Biochemical pharmacology. 2009 Mar 1;77(5):858-66.
C. G. Neochoritis, C. A. Tsoleridis, J. Stephanidou-Stephanatou, C. A. Kontogiorgis, and D. J. Hadjipavlou-Litina, “1,5-Benzoxazepines vs. 1,5-Benzodiazepines. One-pot microwave-assisted synthesis and evaluation for antioxidant activity and lipid peroxidation inhibition,” Journal of Medicinal Chemistry, vol. 53, no. 23, pp. 8409–8420, 2010
Downloads
Published
Issue
Section
License
Copyright (c) 2023 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
